EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes

Marie-Emmanuelle Riviere, Jessica B Langbaum, R Scott Turner, Juha O Rinne, Yihan Sui, Pilar Cazorla, Javier Ricart, Kathleen Meneses, Angelika Caputo, Pierre N Tariot, Eric M Reiman, Ana Graf

Alzheimer's & Dementia · 2024-03 · 20 (3) · 1839-1850

DOI: 10.1002/alz.13532 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 25.12.2023. Verfasst von Marie-Emmanuelle Riviere und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development, Neuroscience, Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Association, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Alzheimer's Prevention Initiative Generation Study 1 evaluated amyloid beta (Aβ) active immunotherapy (vaccine) CAD106 and BACE‐1 inhibitor umibecestat in cognitively unimpaired 60‐ to 75‐year‐old participants at genetic risk for Alzheimer's disease (AD). The study was reduced in size and terminated early. Results from the CAD106 cohort are presented. METHODS Sixty‐five apolipoprotein E ε4 homozygotes with/without amyloid deposition received intramuscular CAD106 450 μg ( n = 42) or placebo ( n = 23) at baseline; Weeks 1, 7, 13; and quarterly; 51 of them had follow‐up Aβ positron emission tomography (PET) scans at 18 to 24 months. RESULTS CAD106 induced measurable serum Aβ immunoglobulin G titers in 41/42 participants, slower rates of Aβ plaque accumulation (mean [standard deviation] annualized change from baseline in amyloid PET Centiloid: −0.91[5.65] for CAD106 versus 8.36 [6.68] for placebo; P < 0.001), and three amyloid‐related imaging abnormality cases (one symptomatic). DISCUSSION Despite early termination, these findings support the potential value of conducting larger prevention trials of Aβ active immunotherapies in individuals at risk for AD. Highlights This was the first amyloid‐lowering prevention trial in persons at genetic risk of late‐onset Alzheimer's disease (AD). Active immunotherapy targeting amyloid (CAD106) was tested in this prevention trial. CAD106 significantly slowed down amyloid plaque deposition in apolipoprotein E homozygotes. CAD106 was generally safe and well tolerated, with only three amyloid‐related imaging abnormality cases (one symptomatic). Such an approach deserves further evaluation in larger AD prevention trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesAlzheimer DiseaseHumansMiddle AgedAgedHomozygoteApolipoprotein E4Plaque, AmyloidAmyloidPositron-Emission TomographyImmunotherapyBrain

Stichwörter der Autor:innen

Alzheimer's diseaseCAD106active immunotherapyamyloidapolipoprotein E genotypebiomarkerscognitively unimpairedpositron emission tomographypreclinicalpreventionvaccine

Substanzen

Amyloid beta-PeptidesApolipoprotein E4Amyloid

Autor:innen und Institutionen

  • Clinical Development, Neuroscience, Novartis Pharma AG, Basel, Switzerland.
  • Banner Alzheimer's Institute, Phoenix, Arizona, USA.
  • Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA.
  • Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.
  • Department of Neurology, CRST - Clinical Research Services Turku, Turku, Finland.
  • Clinical Development, Neuroscience, Novartis Pharmaceuticals, East Hanover, New Jersey, USA.

Förderung

  • NIA NIH HHS
  • Alzheimer's Association
  • National Institute on Aging
  • Foundation for Biomedical Research and Innovation
  • GHR Foundation

Zitieren

APA

Riviere, M. E., Langbaum, J. B., Turner, R. S., Rinne, J. O., Sui, Y., Cazorla, P., Ricart, J., Meneses, K., Caputo, A., Tariot, P. N., Reiman, E. M., & Graf, A. (2024). Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes. Alzheimer's & Dementia, 20(3), 1839-1850. https://doi.org/10.1002/alz.13532

Vancouver

Riviere ME, Langbaum JB, Turner RS, Rinne JO, Sui Y, Cazorla P, et al. Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes. Alzheimer's & Dementia. 2024;20(3):1839-1850. doi:10.1002/alz.13532

BibTeX
@article{Riviere2024,
  author = {Riviere, Marie-Emmanuelle and Langbaum, Jessica B and Turner, R Scott and Rinne, Juha O and Sui, Yihan and Cazorla, Pilar and Ricart, Javier and Meneses, Kathleen and Caputo, Angelika and Tariot, Pierre N and Reiman, Eric M and Graf, Ana},
  title = {Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {3},
  pages = {1839--1850},
  doi = {10.1002/alz.13532}
}
Kostenlos starten →